Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Granules now has a total of 67 ANDA approvals from the USFDA
Subscribe To Our Newsletter & Stay Updated